Please login to the form below

Not currently logged in
Email:
Password:

Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer

CRISPR Therapeutics Marc BeckerCRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

Becker brings over 20 years of commercial, operational and corporate finance expertise to the role, having held senior positions at BankBoston, Genzyme, KPMG and rEVO Biologics.

He joins the Switzerland-headquartered biopharmaceutical company from rEVO Biologics, where he served as its chief financial officer from 2012 until February this year.

While at rEVO, Becker was responsible for leading the finance department, directing the firm's market strategy and managing its governance.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Marc's extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialisation of new breakthrough therapeutics.”

Becker said: “I am excited to join the CRISPR Therapeutics leadership team as the company's growth accelerates with the introduction of strategic partnerships and ventures.

“Our technology is truly revolutionary and I'm delighted to be part of the team that will enable the development of life-changing medicines.”

21st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics